LSTM Home > LSTM Research > LSTM Online Archive

Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.

Evans-Jones, J., Cottle, L., Back, D.J., Gibbons, S., Beeching, Nicholas ORCID: https://orcid.org/0000-0002-7019-8791, Carey, P. and Khoo, S.H. (2010) 'Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.'. Clinical Infectious Diseases, Vol 50, Issue 10, pp. 1419-1421.

Full text not available from this repository.

Abstract

We assessed the risk of clinically significant drug interactions in patients receiving antiretrovirals, and their recognition by physicians. Clinically significant drug interactions were recorded in 27% of 159 patients, with 15% of interactions potentially lowering antiretroviral concentrations. Risk of clinically significant drug interactions was significantly related to receipt of protease inhibitors. Only 36% of clinically significant drug interactions were correctly identified by physicians.

Item Type: Article
Additional Information: Originally published at: http://www.journals.uchicago.edu/doi/abs/10.1086/652149
Subjects: QV Pharmacology > Anti-Inflammatory Agents. Anti-Infective Agents. Antineoplastic Agents > QV 268.5 Antiviral agents (General)
WC Communicable Diseases > Virus Diseases > Acquired Immunodeficiency Syndrome. HIV Infections > WC 503 Acquired immunodeficiency syndrome. HIV infections
WC Communicable Diseases > Virus Diseases > Acquired Immunodeficiency Syndrome. HIV Infections > WC 503.2 Therapy
Digital Object Identifer (DOI): https://doi.org/10.1086/652149
Depositing User: Users 43 not found.
Date Deposited: 15 Jul 2010 11:36
Last Modified: 15 Jun 2018 14:39
URI: http://archive.lstmed.ac.uk/id/eprint/1030

Statistics

View details

Actions (login required)

Edit Item Edit Item